> Details

Tomsitz, Dirk; Ruf, Theresa; Heppt, Markus; Staeger, Ramon; Ramelyte, Egle; Dummer, Reinhard; Garzarolli, Marlene; Meier, Friedegund; Meier, Eileen; Richly, Heike; Gromke, Tanja; Siveke, Jens T.; Franklin, Cindy; Klespe, Kai-Christian; Mauch, Cornelia; Kilian, Teresa; Seegräber, Marlene; Schilling, Bastian; French, Lars E.; Berking, Carola; Heinzerling, Lucie

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
  • Contributor: Tomsitz, Dirk; Ruf, Theresa; Heppt, Markus; Staeger, Ramon; Ramelyte, Egle; Dummer, Reinhard; Garzarolli, Marlene; Meier, Friedegund; Meier, Eileen; Richly, Heike; Gromke, Tanja; Siveke, Jens T.; Franklin, Cindy; Klespe, Kai-Christian; Mauch, Cornelia; Kilian, Teresa; Seegräber, Marlene; Schilling, Bastian; French, Lars E.; Berking, Carola; Heinzerling, Lucie
  • imprint: MDPI AG, 2023
  • Published in: Cancers
  • Language: English
  • DOI: 10.3390/cancers15133430
  • ISSN: 2072-6694
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:p>Background: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting. Patients and Methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM. Results: Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.7 to 3.3) and a median OS of 22 months (95% CI 10.6 to 33.4). In contrast to a published Phase 3 study, our cohort had a higher rate of patients with elevated LDH (65.4% vs. 35.7%) and included patients with prior systemic and local ablative therapies. In patients treated with tebentafusp following ICI, there was a trend for a longer median OS (28 months, 95% CI 26.9 to 29.1) compared to the inverse treatment sequence (24 months, 95% CI 13.0 to 35.0, p = 0.257). The most common treatment-related adverse events were cytokine release syndrome in 71.2% and skin toxicity in 53.8% of patients. Tumor lysis syndrome occurred in one patient. Conclusions: Data from this real-life cohort showed a median PFS/OS similar to published Phase 3 trial data. Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.</jats:p>
  • Access State: Open Access